Streetbeat News

SXTP

60 Degrees Pharmaceuticals, Inc.

Industry

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Open

1.07

Mkt cap

1.8M

Volume

93K

High

1.08

P/E Ratio

-0.62

52-wk high

18.36

Low

0.94

Div yield

N/A

52-wk low

0.70

60 Degrees Pharmaceuticals will sponsor a pilot study of Tafenoquine, the active molecule in its FDA-approved malaria prevention medication, Arakoda, for treating Babesiosis in dogs.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:01 pm

HC Wainwright & Co. analyst Edward White has reiterated a Neutral rating on 60 Degrees (NASDAQ:SXTP).

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 10:57 am

60 Degrees (NASDAQ:SXTP) reported Q4 earnings with a loss of $(0.44) per share, missing the $(0.20) estimate by 120%. However, their sales of $125.68K exceeded the $70.00K estimate by 79.54%.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:01 pm

Westport Fuel Systems Inc. (NASDAQ:WPRT) shares fell by approximately 10% after reporting a Q4 loss wider than expected. Other stocks experienced significant movements, with notable gainers including Stoke Therapeutics, Inc. (NASDAQ:STOK) and losers like Quhuo Limited (NASDAQ:QH). The movements were attributed to various factors including financial results, clinical trial data, and strategic agreements.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 5:45 pm

Stoke Therapeutics, Inc. (STOK) shares surged by approximately 70% in pre-market trading following the announcement of positive Phase 1/2a data for STK-001 in Dravet syndrome. Other stocks also showed significant movement in pre-market trading, with notable gainers including Check-Cap Ltd. (CHEK), C3is Inc. (CISS), and OpGen, Inc. (OPGN), among others. On the losing end, NeuBase Therapeutics, Inc. (NBSE) and AppTech Payments Corp. (APCX) saw substantial declines.

Portfolio Pulse from Avi Kapoor

March 26, 2024 | 12:00 pm

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW) announced the FDA's intention to respond to its babesiosis trial protocol submission in April 2024, a delay from the initially anticipated March 2024. The submission falls under the Company's existing Investigational New Drug application, which does not mandate a response within a specific timeframe. The Company continues to prepare for a June 1, 2024, trial start date.

Portfolio Pulse from Happy Mohamed

March 14, 2024 | 12:07 pm

60 Degrees Pharmaceuticals, Inc. (60P) announced sponsorship of pre-clinical studies to investigate tafenoquine's efficacy against Candida spp, including the drug-resistant Candida auris. The studies, conducted by Monash University, aim to address the urgent need for effective treatments against this emerging pathogen in healthcare settings. Tafenoquine, an anti-malarial drug approved by the FDA in 2018, shows promise due to its unique mode of action. Results are expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 1:09 pm

In Friday's after-market session, several health care stocks showed significant movement. InVivo Therapeutics led the gainers with a 30.1% increase, while Biophytis experienced the largest drop among the losers, falling 13.4%. The movements reflect changes in investor sentiment and market dynamics for these stocks.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 9:31 pm

Health care stocks experienced significant movement in Tuesday's intraday session. NexImmune (NEXI) saw a substantial increase of 152.8%, while 60 Degrees (SXTP) faced a sharp decline of 38.1%. Other notable gainers include PepGen (PEPG) and 2seventy bio (TSVT), with increases of 60.68% and 20.2% respectively. On the losing side, Revelation Biosciences (REVB) and Palisade Bio (PALI) dropped by 32.18% and 32.11%, indicating a volatile day for health care stocks.

Portfolio Pulse from Benzinga Insights

January 30, 2024 | 5:31 pm

JetBlue Airways Corp (NASDAQ:JBLU) shares fell over 5% after reporting Q4 FY23 results with a decline in operating revenue by 3.7% Y/Y to $2.33 billion, beating estimates but with an adjusted loss per share of 19 cents. The company anticipates a revenue decline in Q1 FY24. Other stocks mentioned include Pixelworks, Inc. (NASDAQ:PXLW), Agrify Corporation (NASDAQ:AGFY), Sanmina Corporation (NASDAQ:SANM), Sidus Space, Inc. (NASDAQ:SIDU), 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP), and Calix, Inc. (NYSE:CALX), which experienced significant price movements after various announcements. Crude oil gained 1%, and U.S. stocks traded mostly lower with the Nasdaq Composite down over 50 points.

Portfolio Pulse from Avi Kapoor

January 30, 2024 | 5:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.